In addition, the available Btk inhibitors in combination with Candida colonization might replicate the protective phenotype and thus Btk could be a possible target for the treatment of inflammatory conditions such as ulcerative colitis and Crohn's disease. Here, BTK is linked to ulcerative colitis.